Prostatype Genomics enters the Italian market

Prostatype Genomics can announce a new cooperation that opens up the Italian market for the Prostate cancer test Prostatype®.

The initiative will be led by Maurizio Ballerini MD and is already operational.

Dr. Maurizio Ballerini comments: “I am happy and proud to be able to represent Prostatype Genomics and Prostatype® in Italy. Prostatype® is an innovative and advanced prostate cancer biomarker that will perfectly match the strategy of providing leading products within the prognostic/therapeutic field in Italy. Representing Prostatype® will create great opportunities to get access to healthcare stakeholders and strengthen the commercial opportunities.”

Prostatype Genomics CEO, Fredrik Persson comments: “We are very happy about this set-up. Having a person with Maurizios track record and experience in market development in Italy will give Prostatype® the best possible start in this key market”.

Dr. Maurizio Ballerini will take on the role as Senior Director of Market Development for Prostatype Genomics in Italy. Maurizio has extensive experience from a number of diagnostics companies in different therapeutic areas, where he has held both scientific and commercial roles. Most recently, Maurizio has held leading commercial positions in major diagnostics companies within the field of Prostate cancer.

Media enquiries
fredrik.persson@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.